Get the Stockscreener App
3.08
1.91%
-0.06
After Hours:
3.08
Protara Therapeutics Inc stock is traded at $3.08, with a volume of 123.28K.
It is down -1.91% in the last 24 hours and up +3.36% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.14
Open:
$3.18
24h Volume:
123.28K
Relative Volume:
0.30
Market Cap:
$118.83M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.0922
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
+0.98%
1M Performance:
+3.36%
6M Performance:
-32.31%
1Y Performance:
+36.28%
1-Day Range:
$3.07
$3.20
1-Week Range:
$3.022
$3.225
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.08 | 117.67M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Protara Therapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - Jammu Links News
Is Protara Therapeutics Inc. a good long term investmentMassive profits - Jammu Links News
What drives Protara Therapeutics Inc. stock priceDynamic growth stocks - Jammu Links News
Will Protara Therapeutics Inc. stock split in the near futureFree Stock Market Return Analysis - Newser
Why Protara Therapeutics Inc. stock attracts strong analyst attentionFree Consultation - Newser
What makes Protara Therapeutics Inc. stock price move sharplyMinimized Risk Trading Plan - Newser
How Protara Therapeutics Inc. stock performs during market volatilityStable Stocks With High Yield - Newser
Protara Therapeutics Awards 44,250 Equity Grants Worth $2.80 Per Share to Strategic New Hires - Stock Titan
TARA SEC FilingsProtara Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Protara Therapeutics, Inc.(NasdaqGM: TARA) added to Russell 3000E Index - MarketScreener
Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Buy” by Brokerages - Defense World
Protara Therapeutics (TARA) Drops 3.69% to 2024 Low - AInvest
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Why EchoStar Stock Is Soaring Higher Today - The Globe and Mail
Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025 (NASDAQ:TARA) - Seeking Alpha
SoundHound AI (SOUN): This High-Potential Growth Stock Could Be Your Smartest Bet under $10 - The Globe and Mail
Where Will Uber Stock Be in 5 Years? - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Protara Therapeutics Holds Annual Stockholders Meeting - TipRanks
These 3 ‘Bro Billionaire’ Stocks Are Wildly Outperforming in Trump’s Market - The Globe and Mail
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Cantor Fitzgerald Forecasts TARA FY2026 Earnings - Defense World
Squarepoint Ops LLC Makes New $110,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Steven Hudson buying at ECN Capital (ECN) - The Globe and Mail
Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Buy” by Analysts - Defense World
Why Shares of Tesla Are Sinking Today - The Globe and Mail
Is Costco a Buy Now? - The Globe and Mail
Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics names new Chief Commercial Officer By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Appoints New Chief Commercial Officer | TARA Stock News - GuruFocus
Protara Therapeutics names new Chief Commercial Officer - Investing.com
Protara Therapeutics Names William Conkling as Chief Commercial Officer - MarketScreener
Protara Therapeutics Announces Appointment Of William Conkling As Chief Commercial Officer - marketscreener.com
Protara Therapeutics Announces Appointment of William Conkling a - GuruFocus
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer - GlobeNewswire
Cancer Drug Veteran Behind Trodelvy Launch Joins Protara as Commercial Chief to Lead Market Strategy - Stock Titan
The Next Stock I'm Buying? - The Globe and Mail
Transcript : Protara Therapeutics, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 01 - marketscreener.com
Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation - Nasdaq
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating - GuruFocus
Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Receives Buy Rating with $21 Price T - GuruFocus
Jones Initiates Protara Therapeutics at Buy With $21 Price Target - marketscreener.com
Richard Levy Spends US$64k On Protara Therapeutics Stock - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Dimensional Fund Advisors LP Makes New $111,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):